Tegatrabetan - BetaCat Pharmaceuticals

Drug Profile

Tegatrabetan - BetaCat Pharmaceuticals

Alternative Names: BC-2059; Tegavivint

Latest Information Update: 16 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BetaCat Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Beta catenin inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fibroma
  • Preclinical Acute myeloid leukaemia; Multiple myeloma

Most Recent Events

  • 15 Jul 2018 Phase-I clinical trials in Fibroma (Recurrent, Inoperable/unresectable, Second-line therapy or greater) in USA (IV) (NCT03459469)
  • 21 Apr 2018 Pharmacodynamics data from preclinical trails in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 13 Mar 2018 Beta Cat Pharmaceuticals plans a phase I trial for Fibroma (Recurrent, Inoperable/unresectable, Second-line therapy or greater) in March 2018 (NCT03459469)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top